Cited by 1,249Cancer Immunotherapy and BiomarkersChromatin Remodeling and CancerRenal cell carcinoma treatment

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Open access

Miao, Diana, Margolis, Claire A., Gao, Wenhua, Voss, Martin H., Li, Wei, Martini, Dylan J., Norton, Craig, Bossé, Dominick, Wankowicz, Stephanie M., Cullen, Dana, Horak, Christine, Wind-Rotolo, Megan, Tracy, Adam, Giannakis, Marios, Hodi, Frank Stephen, Drake, Charles G., Ball, Mark W., Allaf, Mohamad E., Snyder, Alexandra, Hellmann, Matthew D., Ho, Thai, Motzer, Robert J., Signoretti, Sabina, Kaelin, William G., Choueiri, Toni K., Van Allen, Eliezer M.·2018·Science

DOI 10.1126/science.aan5951PMC PMC6035749

Open this paper in CoChat — free account

Abstract

SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.aan5951

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658

Show all 57 references

Sorted by citations

Items 601–700 of 1,001

Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Sears, T. J., Pagadala, M. S., Castro, A., Lee, K.-H., Kong, J., Tanaka, K., Lippman, S. M., Zanetti, M., & Carter, H. K. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0164 · Cited by 12
CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II
Chang, Y., & Wu, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae595 · Cited by 12
Immune responses in genomically simple SWI/SNF–deficient cancers
Leruste, A., Chauvin, C., Pouponnot, C., Bourdeaut, F., Waterfall, J. J., & Piaggio, E. (2020) · Cancer · doi:10.1002/cncr.33172 · Cited by 14
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors
Incorvaia, L., Madonia, G., Corsini, L. R., Cucinella, A., Brando, C., Gagliardo, C., Santoni, M., Fanale, D., Inno, A., Fazio, I., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103390 · Cited by 12
Genomic instability in lower-grade glioma: Prediction of prognosis based on lncRNA and immune infiltration
Kang, K., Xie, F., Wu, Y., Chang, H., Bai, Y., Long, J., Lian, X., & Zhang, F. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.07.011 · Cited by 12
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem
McLean, B. J., Istadi, A., Clack, T., Vankan, M., Schramek, D., Neely, G. G., & Pajic, M. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200014 · Cited by 12
Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms
Lim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 12
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11
The renal clear cell carcinoma immune landscape
Saad, O. A., Li, W. T., Krishnan, A. R., Nguyen, G. C., Lopez, J. P., McKay, R. R., Wang‐Rodriguez, J., & Ongkeko, W. M. (2022) · Neoplasia · doi:10.1016/j.neo.2021.12.007 · Cited by 12
Self-citation
Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Cui, Y., Liu, X., Wu, Y., Xiao, L., Dai, J., Zhang, Z., & Guo, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.798401 · Cited by 12
Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC)
Zeng, X., Li, L., Hu, Z., & Peng, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832027 · Cited by 12
The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers
Passeri, T., Gutman, T., Hamza, A., Adle‐Biassette, H., Girard, E., Beaurepere, R., Tariq, Z., Mariani, O., Dahmani, A., Bourneix, C., et al. (2023) · Journal of neurosurgery · doi:10.3171/2023.1.jns222180 · Cited by 11
Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression
Bursch, K. L., Goetz, C. J., Jiao, G., Nuñez, R., Olp, M. D., Dhiman, A., Khurana, M., Zimmermann, M. T., Urrutia, R. A., Dykhuizen, E. C., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107146 · Cited by 11
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
Sepe, P., Mennitto, A., Corti, F., & Procopio, G. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240889 · Cited by 11
Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis
Xie, L., Wu, S., He, R. X., Li, S., Lai, X., & Wang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901662 · Cited by 11
Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis
Obeng, R. C., Arnold, R. S., Ogan, K., Master, V. A., Pattaras, J. G., Petros, J. A., & Osunkoya, A. O. (2020) · International Journal of Urology · doi:10.1111/iju.14302 · Cited by 11
Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer
Vaishampayan, U. N., Shah, H., Asad, M., Shi, D., Dickow, B., Suisham, S., Domina, J., Cher, M. L., Samantray, J., & Aoun, H. D. (2020) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2020.132 · Cited by 12
Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients
Huang, J., Cai, W., Cai, B., Kong, W., Zhai, W., Zhang, J., Chen, Y., Chen, S., Bai, Y., Huang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697219 · Cited by 11
QTL Mapping for Haploid Inducibility Using Genotyping by Sequencing in Maize
Trampe, B., Batîru, G., da Silva, A. P., Frei, U. K., & Lübberstedt, T. (2022) · Plants · doi:10.3390/plants11070878 · Cited by 11
Chromatin regulation and immune escape
Ghorani, E., & Quezada, S. A. (2018) · Science · doi:10.1126/science.aat0383 · Cited by 11
Transcriptional control of kidney cancer
Sanchez, D. J., & Simon, M. C. (2018) · Science · doi:10.1126/science.aau4385 · Cited by 13
Long read sequencing reveals a novel class of structural aberrations in cancers: identification and characterization of cancerous local amplificationsPreprint
Sakamoto, Y., Xu, L., Seki, M., Yokoyama, T., Kasahara, M., Kashima, Y., Ohashi, A., Shimada, Y., Motoi, N., Tsuchihara, K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/620047 · Cited by 12
In-Depth Characterization and Validation in BRG1 -Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin RemodelingPreprint
Jagani, Z., Chenail, G., Xiang, K. X., Bushold, G., Bhang, H. C., Li, A., Elliott, G., Zhu, J., Vattay, A., Gilbert, T. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/812628 · Cited by 11
The expression, regulation, and function of human endogenous retroviruses in genitourinary cancers
Ma, W., Ji, C., Abudushataer, A., Liu, N., Xu, T., Zhao, K., Qian, Y., Tuerxun, P., Jiang, X., Xiong, Z., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02820-2 · Cited by 10
5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma
Chen, C., Chen, L., Zhang, J., & Xu, H. (2022) · Current Oncology · doi:10.3390/curroncol30010044 · Cited by 10
High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis
Lei, P., Zhang, M., Li, Y., & Wang, Z. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.996362 · Cited by 10
Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma
Wu, Z., Jin, M., Xin, P., & Zhang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1293729 · Cited by 10
An atlas of cell-type-specific interactome networks across 44 human tumor types
Li, Z., Liu, G., Yang, X., Shu, M., Jin, W., Tong, Y., Liu, X., Wang, Y., Yuan, J., & Yang, Y. (2024) · Genome Medicine · doi:10.1186/s13073-024-01303-w · Cited by 10
Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma
Xu, Z., Jiang, W., Liu, L., Qiu, Y., Wang, J., Dai, S., Guo, J., & Xu, J. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03681-x · Cited by 10
Mutant ARID1A: igniting cancer immunotherapy
Vokshi, B., & Toska, E. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.07.003 · Cited by 10
TME-NET: an interpretable deep neural network for predicting pan-cancer immune checkpoint inhibitor responses
Ding, X., Zhang, L., Fan, M., & Li, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae410 · Cited by 11
TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma
Li, J., Chen, M., Tong, M., & Cao, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457691 · Cited by 10
Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Owoicho, A. M., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Tchawe, Y. S. N., Uchendu, I. K., Pascal, A. M., Nikitina, N. M., Rusanov, A. S., Sanikovich, V. D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010265 · Cited by 12
PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer
Li, R., He, J., Liu, C., Jiang, Z., Qin, J., Liang, K., Ji, Z., & Zhao, L. (2025) · Theranostics · doi:10.7150/thno.100793 · Cited by 10
Characterization of Exhausted T Cell Signatures in Pan-Cancer Settings
Juthi, R. T., Sazed, S. A., Mareboina, M., Zaravinos, A., & Georgakopoulos‐Soares, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052311 · Cited by 10
The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment
Gaffney, S. G., Perry, E. B., Chen, P.-M., Greenstein, A. E., Kaech, S. M., & Townsend, J. P. (2019) · Oncotarget · doi:10.18632/oncotarget.27027 · Cited by 10
The genetic landscapes of urological cancers and their clinical implications in the era of high‐throughput genome analysis
Light, A., Ahmed, A., Prokar Dasgupta, A., & Elhage, O. (2020) · British Journal of Urology · doi:10.1111/bju.15084 · Cited by 10
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?
Porta, C., Cosmai, L., & Rizzo, M. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000870 · Cited by 10
A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma
Wu, S., & Li, X. (2021) · Bioengineered · doi:10.1080/21655979.2021.1922330 · Cited by 10
Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
Gil, L., Alves, F. R. A., Silva, D., Fernandes, I., Fontes-Sousa, M., Alves, M., Papoila, A. L., & da Luz, R. (2022) · Cureus · doi:10.7759/cureus.22224 · Cited by 10
Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer
Ju, M., Fan, J., Zou, Y., Yu, M., Jiang, L., Wei, Q., Bi, J., Hu, B., Wang, L., Guan, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807840 · Cited by 10
PANK1 associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database
Wang, B., Liu, B., Luo, Q., Sun, D., Li, H., Zhang, J., Jin, X., Cheng, X., Niu, J., Yuan, Q., et al. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-1488 · Cited by 10
Neoantigens and their clinical applications in human gastrointestinal cancers
Eshkiki, Z. S., Agah, S., Tabaeian, S. P., Sedaghat, M., Dana, F., Talebi, A., & Akbari, A. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02776-y · Cited by 10
Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism
Gong, Z., Jia, Q., Guo, J., Li, C., Xu, S., Jin, Z., Chu, H., Wan, Y. Y., Zhu, B., & Zhou, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00371-1 · Cited by 10
ZNF692 promote proliferation through transcriptional repression of essential genes in clear cell renal carcinoma
Wang, H., Zhao, J., He, H., Xie, X., Dai, J., Xu, D., & Huang, X. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.06.014 · Cited by 8
The prognostic landscape of interactive biological processes presents treatment responses in cancer
He, B., Gao, R., Lv, D., Wen, Y., Song, L., Wang, X., Lin, S., Huang, Q., Deng, Z., Wang, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.064 · Cited by 10
Bayesian multiple instance regression for modeling immunogenic neoantigens
Park, S., Wang, X., Lim, J., Xiao, G., Lu, T., & Wang, T. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220914321 · Cited by 10
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer
Cimadamore, A., Aurilio, G., Nolè, F., Massari, F., Scarpelli, M., Santoni, M., Antonio Lopez-beltran, B., Liang Cheng, C., & Montironi, R. (2020) · Cells · doi:10.3390/cells9061495 · Cited by 10
Dissecting the immunogenomic biology of cancer for biomarker development
Allen, E. M. V., & Choueiri, T. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00461-1 · Cited by 10
Self-citation
Clinicopathological and prognostic impact of somatic mutations in Chinese patients with clear cell renal cell carcinoma
Bi, H., Yin, J., Zhou, L., Wu, Y., Ge, L., Lu, M., Liu, L., Zhang, H., Zhao, Y., Liu, C., et al. (2020) · Translational Andrology and Urology · doi:10.21037/tau-20-1410 · Cited by 10
Significance of CD8+ T cell infiltration-related biomarkers and the corresponding prediction model for the prognosis of kidney renal clear cell carcinoma
Tian, Y., Wei, Y., Liu, H., Shang, H., Xu, Y., Wu, T., Liu, W., Huang, A., Dang, Q., & Sun, Y. (2021) · Aging · doi:10.18632/aging.203584 · Cited by 10
Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment
Lin, Y., Pan, X., Chen, Z., Lin, S., Shen, Z., & Chen, S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02342-8 · Cited by 10
Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma
Jee, B., Seo, E., Park, K., Kim, Y. R., Byeon, S., Lee, S. M., Chung, J. H., Song, W., Sung, H. H., Jeon, H. G., et al. (2022) · Cancers · doi:10.3390/cancers14102354 · Cited by 10
Potential Application of Pyroptosis in Kidney Renal Clear Cell Carcinoma Immunotherapy and Targeted Therapy
Qi, X., Che, X., Li, Q., Wang, Q., & Wu, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918647 · Cited by 11
SWI/SNF-deficient Malignancies: Optimal Candidates for Immune-oncological Therapy?
Agaimy, A. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000366 · Cited by 10
The Inflammasomes Adaptor Protein PYCARD Is a Potential Pyroptosis Biomarker Related to Immune Response and Prognosis in Clear Cell Renal Cell Carcinoma
Su, J., Tian, X., Xu, W., Anwaier, A., Ye, S., Zhu, S., Wang, Y., Gu, J., Shi, G., Qu, Y., et al. (2022) · Cancers · doi:10.3390/cancers14204992 · Cited by 10
The PD-1 single‐nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient
Boguszewska-Byczkiewicz, K., Wow, T., Szymańska, B., Kośny, M., & Kołacińska, A. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08423-3 · Cited by 10
Development and validation of a PBRM1‐associated immune prognostic model for clear cell renal cell carcinoma
Chen, J., Yao, C., Qiao, N., Ge, Y., Li, J., Lin, Y., & Yao, S. (2021) · Cancer Medicine · doi:10.1002/cam4.4115 · Cited by 10
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy responsePreprint
Lund‐Andersen, C., Nakken, S., Nygård, S., Fromm, B., Aasheim, L. B., Davidson, B., Julsrud, L., Abrahamsen, T. W., Kristensen, A. T., Dybdahl, B., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003566 · Cited by 10
SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma
Lin, J., Jia, Y., Deng, X. L., Wang, C. S., & Wang, H. S. (2023) · BMC Gastroenterology · doi:10.1186/s12876-022-02633-y · Cited by 9
A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
Kang, H., Zhu, X., Cui, Y., Xiong, Z., Zong, W., Bào, Y., & Jia, P. (2023) · Cancers · doi:10.3390/cancers15164094 · Cited by 12
Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis
Yue, Y., Cai, X., Lu, C., Sechi, L. A., Solla, P., & Li, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1238312 · Cited by 9
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development
Wang, Q., Xie, B., Sun, J., Li, Z., Xiao, D., Tao, Y., & She, X. (2024) · Journal of Cancer · doi:10.7150/jca.92101 · Cited by 9
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication
Pang, L., Zhou, H.-Q., Zhang, Y.-X., Zhuang, W., Pang, F., Chen, L.-J., Liao, J., Huang, Y., Mao, T.-Q., Mai, Z.-H., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103472 · Cited by 11
The prognostic value and its relationship with immune infiltration of ACLY in clear cell renal cell carcinoma
Yin, B., Liu, Q., Zheng, Y., Gao, H., Lin, Y., & Zhao, Z. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102056 · Cited by 9
Molecular Profiling Defines Three Subtypes of Synovial Sarcoma
Chen, Y., Su, Y., Cao, X., Siavelis, I., Leo, I. R., Zeng, J., Tsagkozis, P., Hesla, A. C., Papakonstantinou, A., Liu, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202404510 · Cited by 10
CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma
Fan, Y., Dan, W., Que, T., Wei, Y., Liu, B., Wang, Z., Zhang, Y., Wang, Y., Liu, T., Zhuang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202412967 · Cited by 10
ALB inhibits tumor cell proliferation and invasion by regulating immune microenvironment and endoplasmic reticulum stress in clear cell renal cell carcinoma
Zhu, J.-M., Chen, S., Xu, Y., Gao, R.-C., Cai, H., Zheng, Q., Sun, X., Xue, X., Wei, Y., & Xu, N. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167672 · Cited by 9
The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma
Ye, T., Zhang, J., Liu, X.-Y., Zhou, Y., Yuan, S., Yang, M., Xie, W., Gao, C., Chen, Y., Huang, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785526 · Cited by 9
RRM2 gene expression depends on BAF180 subunit of SWISNF chromatin remodeling complex and correlates with abundance of tumor infiltrating lymphocytes in ccRCC.
Szarkowska, J., Cwiek, P., Szymanski, M., Rusetska, N., Jancewicz, I., Stachowiak, M., Swiatek, M., Łuba, M., Konopiński, R., Kubala, S., et al. (2021) · PubMed Central · Cited by 9
Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment
Wang, A., Yuan, Y., Chu, H., Gao, Y., Jin, Z., Jia, Q., & Zhu, B. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610196 · Cited by 9
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
Keber, C. U., Derigs, M., Schultz, C., Wegner, M., Lingelbach, S., Wischmann, V., Hofmann, R. W., Denkert, C., Hegele, A., & Hänze, J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03166-9 · Cited by 9
Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Kim, J. H., Kim, G. H., Ryu, Y., Kim, S., Kim, H., Yoon, S. K., Cho, Y. M., & Lee, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969569 · Cited by 9
A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma
Zhao, C., Tan, T., Zhang, E., Wang, T., Gong, H., Jia, Q., Liu, T., Yang, X., Zhao, J., Wu, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029670 · Cited by 9
Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort
Liu, Y., Wang, S., Wang, Y., Li, Y., Zhu, X., Lai, X., Zhang, X., Li, X., Xiao, X., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151224 · Cited by 9
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Labaki, C., Saliby, R. M., Bakouny, Z., Saad, E., Semaan, K., Eid, M., Lalani, A. A., Choueiri, T. K., & Braun, D. A. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.021 · Cited by 9
Self-citation
GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1
Cochran, A. G., & Flynn, M. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01149 · Cited by 9
In situ conversion of defective Treg into SuperTreg cells to treat advanced IPEX-like disorders in mice
Li, Y., Chen, Y., Mao, S., Kaundal, R. K., Jing, Z., Chen, Q., Wang, X., Xia, J., Liu, D., Sun, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15836-2 · Cited by 9
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond
Miron, B., Xu, D., & Zibelman, M. R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040225 · Cited by 9
Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma
Doshi, S. D., Oza, J. H., Remotti, H. E., Remotti, F., Moy, M. P., Schwartz, G. K., & Ingham, M. A. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00201 · Cited by 9
Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
van Oost, S., Meijer, D. M., Kuijjer, M. L., Bovée, J. V. M. G., & de Miranda, N. F. C. C. (2021) · Biomedicines · doi:10.3390/biomedicines9081048 · Cited by 9
Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma
Xu, W., Zhu, W., Tian, X., Liu, W., Wu, Y., Anwaier, A., Su, J., Wei, S., Qu, Y., Zhang, H., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.772436 · Cited by 10
HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinoma
Guo, T., Wang, T., Zhang, J., Chen, S., & Wang, X. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101554 · Cited by 9
MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
Zhou, Y. C., Tan, Y., Zhang, Q., Duan, Q., & Chen, J. (2022) · European journal of medical research · doi:10.1186/s40001-022-00856-z · Cited by 10
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
Flynn, M., Pickering, L. M., Larkin, J., & Turajlic, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918777427 · Cited by 9
Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts
Iafolla, M. A. J., Picardo, S. L., Aung, K. L., & Hansen, A. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222359 · Cited by 9
A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma
Fan, L., Hu, W., Zhang, W., Li, G., & Guo, Y. (2020) · Disease Markers · doi:10.1155/2020/8352809 · Cited by 9
Corrigendum: Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
Hou, T., Jiang, S., Wang, Y., Xie, Y., Zhang, H., Feng, Y., Ma, F., Ma, J., Liu, X., & Hu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705406 · Cited by 9
Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction
Li, H., Sun, X., Zhao, Y., Zhang, C., Jiang, K., Ren, J., Xing, L., & He, M. (2023) · BMC Cancer · doi:10.1186/s12885-023-11015-w · Cited by 8
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani, Y. C., Jansen, C. S., Gerke, M. B., & Bilen, M. A. (2024) · Immunotherapy · doi:10.2217/imt-2023-0267 · Cited by 8
Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment
Yang, Y., Zeng, S., & Hu, X. (2024) · APOPTOSIS · doi:10.1007/s10495-023-01933-2 · Cited by 8
THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data
Wang, Y., Guan, Y., Lai, X., Liu, Y., Chang, Z., Wang, X., Wang, Q., Liu, J., Zhao, J., Yang, S., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae648 · Cited by 8
A comprehensive insights of cancer immunotherapy resistance
Das, L., & Das, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02605-8 · Cited by 9
Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma
Kowalewski, A., Zdrenka, M., Grzanka, D., & Szylberg, Ł. (2020) · Cancers · doi:10.3390/cancers12113300 · Cited by 8
Transcriptomic signatures of tumors undergoing T cell attack
Gokuldass, A., Schina, A., Lauss, M., Harbst, K., Chamberlain, C. A., Draghi, A., Westergaard, M. C. W., Nielsen, M., Papp, K., Sztupinszki, Z. M., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03015-1 · Cited by 8
A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response
Weir, W. H., Mucha, P. J., & Kim, W. Y. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100602 · Cited by 9
A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma
Peng, L., Liang, J., Wang, Q., & Chen, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.798846 · Cited by 8
Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study
Liu, D. H., Dani, K., Reddy, S. S., Lei, X., Demirjian, N. L., Hwang, D., Varghese, B. A., Rhie, S. K., Yap, F. Y., Quinn, D. I., et al. (2023) · Oncology · doi:10.1159/000530719 · Cited by 9
MPP7 is a potential prognostic marker and is associated with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a bioinformatics analysis based on the TCGA database
Cheng, X., Sun, D., Li, H., Zhang, J., Luo, Q., Jin, X., Chen, Y., Yuan, Q., & Wang, B. (2023) · Translational Andrology and Urology · doi:10.21037/tau-23-166 · Cited by 7

Authors: Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, M. D., Ho, T., Motzer, R. J., Signoretti, S., Kaelin, W. G., Choueiri, T. K., & Van Allen, E. M.
Affiliations: Broad Institute (US)
Dana-Farber Cancer Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bristol-Myers Squibb (United States) (US)
Bristol-Myers Squibb, New York, NY 10154, USA.
Columbia University Irving Medical Center (US)
Johns Hopkins University (US)
Mayo Clinic in Arizona (US)
Howard Hughes Medical Institute (US)
Corresponding author: Choueiri, Toni K.
ORCID: Miao, Diana
Margolis, Claire A.
Gao, Wenhua
Voss, Martin H.
Li, Wei
Martini, Dylan J.
Bossé, Dominick
Wind-Rotolo, Megan
Tracy, Adam
Giannakis, Marios
Hodi, Frank Stephen
Drake, Charles G.
Ball, Mark W.
Allaf, Mohamad E.
Snyder, Alexandra
Hellmann, Matthew D.
Ho, Thai
Motzer, Robert J.
Signoretti, Sabina
Kaelin, William G.
Choueiri, Toni K.
Van Allen, Eliezer M.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2018-02-16
Volume: 359
Issue: 6377
Pages: 801-806
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.aan5951
PMC: PMC6035749
OpenAlex: W2782183686
Cited by: 1,249
References: 57
Citations by year: 2026: 73 · 2025: 93 · 2024: 153 · 2023: 164 · 2022: 186 · 2021: 195 · 2020: 179 · 2019: 113 · 2018: 89
FWCI: 54.48
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (K08 CA188615, U24CA224316)
Howard Hughes Medical Institute (Medical Research Fellowship)
American Association for Cancer Research (KureIt Grant for Kidney Research)
NIH Office of the Director (P30 CA008748)
Bristol-Myers Squibb (II-ON Consortium)
Dana-Farber Cancer Institute (Loker Pinard Funds for Kidney Cancer Research)
Dana-Farber/Harvard Cancer Center (Kidney SPORE)
BroadNext10
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: clear cell renal cell carcinoma, immune checkpoint inhibitors, SWI/SNF complex, PBRM1 mutation, tumor response prediction, antitumor immunity, interferon-gamma, T cell-mediated killing, metastatic renal cell carcinoma, cancer genomics
MeSH terms: Carcinoma, Renal Cell, Chromosomal Proteins, Non-Histone, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Transcription Factors, Cohort Studies, Gene Expression Profiling, Genomics, Exome, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks